FDA Clearance Tracker · P990056-S037
Elecsys total PSA
Last checked: Nov 20, 2026Latest source record: May 12, 2020 (this decision)Source: openFDAMethods & limitations
Decided
May 12, 2020
Approved
Time to decision
180 days
Received Nov 14, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990056-S037
- Device name
- Elecsys total PSA
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Nov 14, 2019
- Decided
- May 12, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990056
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the update of the Elecsys total PSA immunoassay to improve the tolerance to biotin interference.
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.